Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 1,009,763 | 1,026,117 | 1,011,560 | 1,013,476 | 1,026,623 |
| Cost of Goods | 660,742 | 672,404 | 666,717 | 649,391 | 664,783 |
| Gross Profit | 349,021 | 353,713 | 344,843 | 364,085 | 361,840 |
| Operating Expenses | 232,358 | 202,465 | 219,583 | 231,554 | 211,121 |
| Operating Income | 117,405 | 151,652 | 125,977 | 132,922 | 151,502 |
| Interest Expense | 30,284 | 32,769 | 35,001 | 33,544 | 33,742 |
| Other Income | 4,120 | 770 | 8,035 | 109,328 | -4,887 |
| Pre-tax Income | 91,241 | 119,653 | 99,011 | 208,706 | 112,873 |
| Income Tax | 20,946 | 25,392 | 24,529 | 19,754 | 24,852 |
| Net Income Continuous | 70,295 | 94,261 | 74,482 | 188,952 | 88,021 |
| Minority Interests | 1,017 | 180 | 1,522 | 1,868 | 632 |
| Net Income | $69,278 | $94,081 | $72,960 | $187,084 | $87,389 |
| EPS Basic Total Ops | 1.34 | 1.75 | 1.31 | 3.66 | 1.70 |
| EPS Basic Continuous Ops | 1.37 | 1.83 | 1.45 | 3.68 | 1.72 |
| EPS Diluted Total Ops | 1.33 | 1.74 | 1.30 | 3.63 | 1.69 |
| EPS Diluted Continuous Ops | 1.36 | 1.82 | 1.44 | 3.68 | 1.71 |
| EPS Diluted Before Non-Recurring Items | 2.59 | 2.80 | 2.27 | 2.46 | 2.72 |
| EBITDA(a) | $205,603 | $237,734 | $211,334 | $213,436 | $230,372 |